AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH

This study is an open label, multicenter study. Subjects are randomized at a 1:1 ratio to receive either (arm A) azacitidine administered IH at day 1-5 and chidamide admistered twice a week for two weeks in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or (arm B) CHOP administered every 3 weeks for 6 cycles in patients with previously untreated peripheral T-cell lymphoma.

NCT Number	NCT05678933
Lead Sponsor	Tianjin Medical University Cancer Institute and Hospital
Conditions	Peripheral T-cell Lymphoma Targeted Therapy
Enrollment	200 participants
Start Date	2023-01-01
Primary Completion	2027-12-01 (estimated)
Study Completion	2029-12-01 (estimated)
Updated on ClinicalTrials.gov	2023-01-10